Allogene Therapeutics (ALLO) Tax Provisions (2018 - 2019)
Allogene Therapeutics (ALLO) posted Tax Provisions of -$131000.0 for Q4 2019, up 34.5% sequentially from -$200000.0 in Q2 2019, and down 11.97% YoY from -$148805.8 in Q4 2018.
Powered by 
Analysis
Allogene Therapeutics (ALLO) Tax Provisions (2018 - 2019) Analysis & Trends
Allogene Therapeutics has reported Tax Provisions for 2 years, with the latest figure at -$131000.0 in Q4 2019.
- Quarterly Tax Provisions fell 11.97% year-over-year to -$131000.0 in Q4 2019, while the trailing twelve-month figure through Sep 2020 was -$131000.0 (up 64.31% YoY) and the FY2024 annual result came in at $443000.0, changed N/A from the prior year.
- Tax Provisions advanced to -$131000.0 in Q4 2019 per ALLO's latest filing, from -$200000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at -$50000.0 in Q1 2019 and troughed at -$200000.0 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Allogene Therapeutics | 647.99 Mn | 647.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -131,000.00 |
| Sep 30, 2019 | 33,000.00 |
| Jun 30, 2019 | -200,000.00 |
| Mar 31, 2019 | -100,000.00 |
| Dec 31, 2018 | -117,000.00 |